Media coverage about Kindred Biosciences (NASDAQ:KIN) has been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Kindred Biosciences earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.9965117803926 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Kindred Biosciences (NASDAQ:KIN) traded up $0.20 during mid-day trading on Monday, reaching $7.45. The company’s stock had a trading volume of 71,956 shares, compared to its average volume of 86,597. Kindred Biosciences has a 52-week low of $3.90 and a 52-week high of $9.65.
Kindred Biosciences (NASDAQ:KIN) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. equities analysts predict that Kindred Biosciences will post -1.18 EPS for the current year.
Separately, Zacks Investment Research lowered Kindred Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Kindred Biosciences currently has an average rating of “Buy” and an average target price of $9.19.
WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Kindred Biosciences (KIN) Share Price” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/11/06/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-kindred-biosciences-kin-share-price.html.
About Kindred Biosciences
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
What are top analysts saying about Kindred Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kindred Biosciences Inc. and related companies.